Cigna Ozempic or Wegovy Denied? GLP-1 Weight Loss Appeal Guide

GLP-1 medications like Ozempic (semaglutide) and Wegovy have transformed obesity treatment — but Cigna denies these prescriptions at high rates, citing BMI thresholds, step therapy requirements, and plan exclusions. If your GLP-1 prescription was denied, understanding Cigna's specific coverage policy and the legal tools available to you provides a direct path to an effective appeal. Obesity is recognized as a chronic disease by the American Medical Association, and GLP-1 medications represent established medical treatment — not a lifestyle preference.

Why Insurers Deny GLP-1 Weight Loss Medication Claims

Cigna governs obesity and weight management treatment through Clinical Policy Bulletin (CPB) 0618, publicly available at cigna.com/healthcare-professionals. For GLP-1 receptor agonists used for chronic weight management — Wegovy (semaglutide 2.4mg), Saxenda (liraglutide 3mg), Qsymia, Contrave — CPB 0618 generally requires a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, hyperlipidemia, obstructive sleep apnea, or cardiovascular disease. CPB 0618 also requires evidence that a physician-supervised weight management program has been attempted without adequate results.

Ozempic vs. Wegovy: Ozempic (semaglutide 0.5mg, 1mg, 2mg) is FDA-approved for type 2 diabetes management, not obesity. When prescribed for weight loss in a non-diabetic patient, Cigna will almost always deny it. Wegovy (the higher-dose 2.4mg semaglutide) is FDA-approved specifically for chronic weight management and triggers different coverage criteria.

Step therapy not met: CPB 0618 requires evidence of failed prior supervised weight loss interventions. Cigna wants specific documented attempts — not vague references to "diet and exercise." Specific dates, program names, attendance records, and weight progression data are required.

Plan exclusion: Some employer plans categorically exclude weight loss medications. This is a plan design choice, not a clinical determination. Under ERISA, you can challenge whether this exclusion violates the ACA's essential health benefits requirements for your plan type, or request that your HR department reconsider the exclusion at open enrollment.

How to Appeal

Step 1: Request CPB 0618 and Your Plan's Pharmacy Formulary

Identify which GLP-1 medications are covered and under what tier and Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization criteria. Compare the denial reason against CPB 0618's specific requirements to understand exactly which criterion was cited.

Step 2: Have Your Physician Write a Detailed Medical Necessity Letter

The letter must specifically address each CPB 0618 criterion: your documented BMI and date of measurement, comorbidities with supporting lab results (HbA1c, fasting glucose, lipid panel, blood pressure), and clinical rationale for why GLP-1 therapy specifically is appropriate for your case.

Step 3: Document Failed Prior Treatments Comprehensively

Include records of supervised weight management program participation with specific dates, program names, attendance records, dietary counseling notes, and weight progression data. Vague references will not satisfy CPB 0618. If prior medications were tried, document dates, dosages, duration, and specific reasons for discontinuation or inadequate response.

Step 4: File a Level 1 Internal Appeal Within 180 Days

Include all clinical documentation and directly address each reason cited in the denial. Cite the FDA approval for the specific medication prescribed and ACOG or Obesity Medicine Association guidelines supporting treatment for patients with your BMI and comorbidity profile.

Step 5: Request Peer-to-Peer Review

Have your prescribing physician request a direct conversation with Cigna's pharmacy reviewer. This physician-to-physician discussion is often the most efficient pathway to authorization for GLP-1 medications, particularly when cardiovascular benefits beyond weight loss are relevant to your clinical profile.

Step 6: Request a Step Therapy Exception if Applicable

If Cigna requires you to fail additional medications that your physician believes are medically contraindicated or clinically inappropriate for your situation, your physician should explicitly state this in a step therapy exception request. Most state step therapy laws provide an exception when required prior medications pose clinical risks or are clinically contraindicated.

What to Include in Your Appeal

• CPB 0618 from cigna.com/healthcare-professionals, with the specific criterion at issue identified
• Current height, weight, and BMI from physician records, including date of measurement
• Lab results documenting comorbidities: HbA1c, fasting glucose, lipid panel, blood pressure measurements
• Records of physician-supervised weight loss program participation with dates, weights, dietary counseling notes, and program summaries
• Prior medication trial documentation if applicable — dates, dosages, duration, and specific reasons for discontinuation
• Prescribing physician's letter addressing each CPB 0618 criterion and the clinical rationale for GLP-1 therapy

Fight Back With ClaimBack

Cigna GLP-1 and Ozempic denials are often reversible when the medical record clearly documents BMI criteria, comorbidities, and prior treatment history matching CPB 0618's requirements. The American Medical Association's recognition of obesity as a chronic disease, combined with FDA approval of semaglutide 2.4mg for weight management, makes a denial based on missing documentation rather than clinical appropriateness especially challengeable. ClaimBack generates a professional appeal letter in 3 minutes that directly addresses each CPB 0618 criterion in your specific case.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal